Have you been paying attention to shares of Vertex (VERX)? Shares have been on the move with the stock up 28.9% over the past month. The stock hit a new 52-week high of $55.52 in the previous session.

The Vertices'N'Faces structure (VNF) holds the data used by polyhedron() to construct objects: a vertex list and a list of faces. This library makes it easier to construct polyhedra by providing ...

Vertex Pharmaceuticals (VRTX) reported $2.77 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 11.6%. EPS of $4.38 for the same period compares to ...

The $2.2 million therapy has come a long way since its groundbreaking sickle cell disease FDA approval in December and subsequent January nod in beta thalassemia. As Vertex looks to tap into the ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals VRTX we detected 8 trades. If we ...

For the quarter ended September 2024, Vertex (VERX) reported revenue of $170.44 million, up 17.5% over the same period last year. EPS came in at $0.16, compared to $0.10 in the year-ago quarter.

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at $472.80.

Vertex Pharmaceuticals beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday. Please watch the video at Investors.com - How To ...